Tap a claim on the ring to put it at the centre.
← There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it.
17 connected korrents · 15 moments from 15 Jul 2021 to 18 Sept 2026.
Everything filed under AI and science
AI and science
Everything filed under LLMs
LLMs
Everything filed under investing
investing
Everything filed under infrastructure
infrastructure
Everything filed under developer tools
developer tools Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Read this korrent: There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. Last stated 2 years ago
14 Oct 2024
DL
Derek Lowe — holds since 2024-10-14 — tap for who they are
Same subject: A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. — tap to centre the map on it A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. Last stated 2 years ago
13 May 2024
DL
Derek Lowe — holds since 2024-05-13 — tap for who they are
Same subject: AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech. — tap to centre the map on it AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech. Last stated 11 months ago
23 Nov 2025
EH
Elliot Hershberg — holds since 2025-11-23 — tap for who they are
Same subject: Even the most advanced AI cannot be followed blindly in investing, where value added is zero-sum and what is widely known is therefore worth little. — tap to centre the map on it Even the most advanced AI cannot be followed blindly in investing, where value added is zero-sum and what is widely known is therefore worth little. Last stated 4 months ago
10 Jun 2026
RD
Ray Dalio — holds since 2026-06-10 — tap for who they are
Same subject: The local AI model ecosystem is worth investing in now. — tap to centre the map on it The local AI model ecosystem is worth investing in now. Last stated 4 months ago
15 Jun 2026
VB
Vicki Boykis — holds since 2026-06-15 — tap for who they are
Same subject: AI cannot get a product to the quality bar on its own, because it still works in the realm of averages. — tap to centre the map on it AI cannot get a product to the quality bar on its own, because it still works in the realm of averages. Last stated a year ago
16 Oct 2025
DF
Dylan Field — holds since 2025-10-16 — tap for who they are
Same subject: People have grown accustomed to AI being non-deterministic and occasionally wrong, so it carries little brand risk anymore. — tap to centre the map on it People have grown accustomed to AI being non-deterministic and occasionally wrong, so it carries little brand risk anymore. Last stated a month ago
18 Sept 2026
HD
Horace Dediu — holds since 2026-09-18 — tap for who they are
Same subject: Most of the value an AI expert brings to a company is telling it not to use AI. — tap to centre the map on it Most of the value an AI expert brings to a company is telling it not to use AI. Last stated a year ago
17 Oct 2025
AK
Andrej Karpathy — holds since 2025-10-17 — tap for who they are
Same subject: AI connectors, approached holistically, are now worth adopting despite their gaps and shortfalls. — tap to centre the map on it AI connectors, approached holistically, are now worth adopting despite their gaps and shortfalls. Last stated 2 months ago
13 Aug 2026
TF
Tiago Forte — holds since 2026-08-13 — tap for who they are
Same subject: A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck. — tap to centre the map on it A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck. Last stated 2 years ago
17 Sept 2024
AT
Alex Telford — holds since 2024-09-17 — tap for who they are
Same subject: A computational method can regularly predict protein structures with atomic accuracy even when no similar structure is known. — tap to centre the map on it A computational method can regularly predict protein structures with atomic accuracy even when no similar structure is known. Last stated 5 years ago
15 Jul 2021
DH
Demis Hassabis — holds since 2021-07-15 — tap for who they are
Same subject: A million copies of one researcher would hit diminishing returns quickly, because what research needs is people who think differently. — tap to centre the map on it A million copies of one researcher would hit diminishing returns quickly, because what research needs is people who think differently. Last stated 11 months ago
25 Nov 2025
IS
Ilya Sutskever — holds since 2025-11-25 — tap for who they are
Same subject: Accurate computational approaches are needed to close the protein structural coverage gap and enable large-scale structural bioinformatics. — tap to centre the map on it Accurate computational approaches are needed to close the protein structural coverage gap and enable large-scale structural bioinformatics. Last stated 5 years ago
15 Jul 2021
DH
Demis Hassabis — holds since 2021-07-15 — tap for who they are
Same subject: AI models can be more accurate than physical experiments by averaging out noise, incorporating priors from large datasets, and interpolating between data points. — tap to centre the map on it AI models can be more accurate than physical experiments by averaging out noise, incorporating priors from large datasets, and interpolating between data points. Last stated 11 months ago
23 Nov 2025
EH
Elliot Hershberg — holds since 2025-11-23 — tap for who they are
Same subject: AI will not produce a big breakthrough in biological understanding any time soon, because biology has nothing like the clean, complete, high-quality data that made protein-structure prediction work. — tap to centre the map on it AI will not produce a big breakthrough in biological understanding any time soon, because biology has nothing like the clean, complete, high-quality data that made protein-structure prediction work. Last stated 2 years ago
19 Sept 2024
DL
Derek Lowe — holds since 2024-09-19 — tap for who they are
Same subject: AI could compete with human mathematicians once it acquires a mathematical sense of smell: knowing which way of splitting a problem makes it easier rather than harder. — tap to centre the map on it AI could compete with human mathematicians once it acquires a mathematical sense of smell: knowing which way of splitting a problem makes it easier rather than harder. Last stated a year ago
14 Jun 2025
TT
Terence Tao — holds since 2025-06-14 — tap for who they are
Same subject: AI excels at breadth and human experts at depth, which makes them complementary and makes today's depth-focused way of doing science the wrong shape. — tap to centre the map on it AI excels at breadth and human experts at depth, which makes them complementary and makes today's depth-focused way of doing science the wrong shape. Last stated 7 months ago
20 Mar 2026
TT
Terence Tao — holds since 2026-03-20 — tap for who they are
Same subject: AI in chess and mathematics does not explain anything; it says which position is better, and humans build the theory from that. — tap to centre the map on it AI in chess and mathematics does not explain anything; it says which position is better, and humans build the theory from that. Last stated a year ago
14 Jun 2025
LF
Lex Fridman — holds since 2025-06-14 — tap for who they are
At the centre
There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it.
Holds Read this korrent →
A compound's AI origin story is not by itself a reason to expect it to do better in the clinic.
Holds
AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech.
Holds
Even the most advanced AI cannot be followed blindly in investing, where value added is zero-sum and what is widely known is therefore worth little.
Holds
The local AI model ecosystem is worth investing in now.
Holds
AI cannot get a product to the quality bar on its own, because it still works in the realm of averages.
Holds
People have grown accustomed to AI being non-deterministic and occasionally wrong, so it carries little brand risk anymore.
Holds
Most of the value an AI expert brings to a company is telling it not to use AI.
Holds
AI connectors, approached holistically, are now worth adopting despite their gaps and shortfalls.
Holds
A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck.
Holds
A computational method can regularly predict protein structures with atomic accuracy even when no similar structure is known.
Holds
A million copies of one researcher would hit diminishing returns quickly, because what research needs is people who think differently.
Holds
Accurate computational approaches are needed to close the protein structural coverage gap and enable large-scale structural bioinformatics.
Holds
AI models can be more accurate than physical experiments by averaging out noise, incorporating priors from large datasets, and interpolating between data points.
Holds
AI will not produce a big breakthrough in biological understanding any time soon, because biology has nothing like the clean, complete, high-quality data that made protein-structure prediction work.
Holds
AI could compete with human mathematicians once it acquires a mathematical sense of smell: knowing which way of splitting a problem makes it easier rather than harder.
Holds
AI excels at breadth and human experts at depth, which makes them complementary and makes today's depth-focused way of doing science the wrong shape.
Holds
AI in chess and mathematics does not explain anything; it says which position is better, and humans build the theory from that.
Holds